Gene regulatory pattern analysis reveals essential role of core transcriptional factors’ activation in triple-negative breast cancer

Li Min¹,²,³,*; Cheng Zhang¹,*; Like Qu¹; Jialiang Huang²,³; Lan Jiang²,³; Jiafei Liu¹; Luca Pinello²,³; Guo-Cheng Yuan²,³; Chengchao Shou¹

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departments of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing 100036, P. R. China
²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
³Harvard T. H. Chan School of Public Heath, Boston, MA 02115, USA

*These authors have contributed equally to this work

Correspondence to: Chengchao Shou, email: scc@bjcancer.org
Guo-Cheng Yuan, email: gcyuan@jimmy.harvard.edu

Keywords: gene regulatory pattern, network analysis, transcriptional factors, TNBC

Received: October 27, 2016   Accepted: January 10, 2017   Published: February 27, 2017

ABSTRACT

Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype. Genome-scale molecular characteristics and regulatory mechanisms that distinguish TNBC from other subtypes remain incompletely characterized.

Results: By combining gene expression analysis and PANDA network, we defined three different TF regulatory patterns. A core TNBC-Specific TF Activation Driven Pattern (TNBCac) was specifically identified in TNBC by computational analysis. The essentialness of core translational factors (TF) in TNBC was highlighted and validated by cell proliferation analysis. Furthermore, 13 out of 35 co-targeted genes were also validated to be targeted by ZEB1, MZF1 and SOX10 in TNBC cell lines by real-time quantitative PCR. In three breast cancer cohorts, non-TNBC patients could be stratified into two subgroups by the 35 co-targeted genes along with 5 TFs, and the subgroup that more resembled TNBC had a worse prognosis.

Methods: We constructed gene regulatory networks in breast cancer by Passing Attributes between Networks for Data Assimilation (PANDA). Co-regulatory modules were specifically identified in TNBC by computational analysis, while the essentialness of core translational factors (TF) in TNBC was highlighted and validated by in vitro experiments. Prognostic effects of different factors were measured by Log-rank test and displayed by Kaplan-Meier plots.

Conclusions: We identified a core co-regulatory module specifically existing in TNBC, which enabled subtype re-classification and provided a biologically feasible view of breast cancer.

INTRODUCTION

Breast cancer subtyping was widely used in clinical decisions, such as relapse risk evaluation and treatment selection [1, 2]. According to the evaluation of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2/ERBB2/Neu), breast cancers are routinely divided into hormone receptor positive, HER-2/Neu amplified, and triple-negative breast cancer (TNBC) subtypes [2–4]. TNBC is particularly aggressive, thus often associated with relapse and the worst prognosis [3]. Due to a lack of appropriate molecular targets, TNBC patients could not benefit from endocrine or HER2-targeted therapy [5–7].

Multiple molecular characteristics of TNBC have been well identified [8–12], however, most studies were conducted from the perspective of gene expression, which cannot reflect the whole scope of pathologic mechanisms.
on gene regulation level, consequently, many questions of TNBC remain unanswered [13]. Recent systemic-level network analyses have been applied for diseases study and provide significant insights [14–16]. By incorporating multiple sources of data to model biological processes, especially transcriptional factor (TF) -gene regulatory networks, integrative analyses show promising perspective in comprehending of pathophysiologic mechanisms and developing novel and precise therapies [16, 17]. Among the multiple integration tools, Passing Attributes between Networks for Data Assimilation (PANDA) has better performance and higher accuracy [18–22]. PANDA predicts TF-gene regulatory relationships by integrating information from protein-protein interaction (PPI), gene expression, and TF-sequence-motif data using a message-passing approach, and it has been successfully used to study several diseases including Chronic Obstructive Pulmonary Disease (COPD) [23] and ovarian cancer [24].

In this study, we applied PANDA to characterize the gene regulatory network underlying TNBC, integrating datasets from The Cancer Genome Atlas (TCGA) database [25, 26]. In addition, we validated our predictions by using independent datasets obtained from Cancer Cell Line Encyclopedia (CCLE) [27, 28], Achilles [29, 30], Gene Expression Omnibus (GEO) [31] and Netherlands Cancer Institute (NKI) [32]. Our network approach identified a previously unrecognized core module containing 5 TFs and 35 target genes, thereby providing new mechanistic insights into TNBC. These insights are useful for prognosis as well as development of new therapeutic methods.

RESULTS

Building TF-target regulatory networks of NORM, nTNBC and TNBC

Expression data for 63 NORM, 445 nTNBC and 89 TNBC tissue samples were extracted from TCGA. Robust multichip average (RMA) method [12, 33] was used for normalization and all probes were mapped to Ensembl Gene Symbols by R package mygene. Separate TF-target regulatory networks for the three tissue types were constructed by PANDA. An overview of the analysis pipeline is shown in Figure 1.

For each TF-target edge, a Z-score was given to reflect the confidence level of the potential regulatory relationship. Distribution of Z-scores in different groups was shown in Figure 2A. All edges with an FDR-adjusted p<0.05 were considered significant and used for the subsequent analysis. The overlap of significant edges between the tissue-specific networks was displayed as a Venn diagram (Figure 2B). More than 80% of TF-target edges were commonly shared among all three networks, indicating strong conservation, much higher compared to the overlap of differently expressed genes (Figure 2C).

Furthermore, ENCODE data were downloaded to validate the TF-target edges identified from our computational analysis. Since only two breast cancer cell lines were available in the ChIP-seq database, we chose to verify common edges in all cancer cells rather than in breast cancer cells only. For each TF, its target genes in each cell line were determined as those containing at least one peak in its promoter region (defined as [−750,+250] base-pairs around the transcription start site of an Ensembl Gene). Genes targeted in more than five cell lines were considered as common targets. We then compared the overlap between the ChIPseq-defined target genes and those predicted by PANDA. Take JUN, an evolutionarily conservative TF as an example, most of its common targets were ranked among the top 20% in our PANDA predicted networks (Figure 2D–2L, AUC>0.6), indicating our predictions were reasonable although not completely accurate. The complete results for validation were shown in Supplementary Figure 1.

Identification and TFs co-regulation analysis of three distinct patterns

All genes’ expression profiles were pairwisely compared among NORM, nTNBC and TNBC by t-test, while genes with FDR<0.1 were considered differentially expressed. By combining the differential expression data and three networks together, three regulatory patterns were identified (Figure 1B): First, the Universal Malignancy Progression Pattern (UM) was defined as general biological processes during tumor progression, for which both TF and its targets were stepwise up/down-regulated from NORM to nTNBC to TNBC, in accordance with tissue malignancy change. These links are shared in all three tissue types (Figure 1B, first line). Second, the TF Overexpression Driven TNBC-Specific Pattern (TNBCov) was defined as those edges for which both the TF and its targets were up/down-regulated only in TNBC tissues (Figure 1B, second line). This pattern is associated with the effect of TF over-expression. Third, the TF Activation Driven TNBC-Specific Pattern (TNBCac) was defined as those edges for which the TF-target links were present only in the TNBC networks and the target genes were differentially expressed only in TNBC tissues (Figure 1B, third line). This pattern mimics a driving process in TNBC caused by TNBC specific TF activation or other functional changes.

Co-regulation of all three patterns was shown in a CIRCOS-like plot (Figure 3A). Venn diagrams show overlaps of TFs and target genes in these three patterns (Figure 3B and 3C). Neither the TFs nor the target genes in TNBCov pattern had any overlap with the UM pattern, which is in accordance with their definitions. TFs in all three patterns were mostly unique, indicating that the patterns were tissue specific.
Figure 1: Outline of pattern finding approach. A. Conceptual illustration summary of network construction and data processing; B. Cartoon chart to exhibit different regulation pattern we defined.

| Pattern Name                              | TF Gene Category | Target Gene Category | Regulatory Relationship Category |
|-------------------------------------------|-----------------|----------------------|---------------------------------|
| Universal Malignancy Progression Pattern (UM) | | | |
| TNBC Specific TF Overexpression Driven Pattern (TNBCov) | | | |
| TNBC Specific TF Activation Driven Pattern (TNBCac) | | | |
TF target profile similarity analysis was performed to identify TFs co-regulation modules. Target profile similarity between TFs in the UM, TNBCov, and TNBCac pattern and all the three together was shown by consistency heatmap (Figure 4A–4D). TF co-regulation modules in different patterns were identified and summarized in Table 1. Representative two-TF co-regulation, three-TF co-regulation, and largest TFs co-regulation in different patterns were shown by a Venn diagram (Figure 4E).

Of note, three patterns identified from our network analysis had very different topological differences. For the UM pattern, a gene was typically regulated by few TFs, but many TFs tend to share a common set of target genes for the TNBCac pattern.

**Functional analysis of TNBCac core genes and target genes in all three patterns**

In the co-regulation analysis, we noticed that five TFs (SOX10, M2F1, ZEB1, ETS1, GATA2) shared most of their target genes together (35 target genes were identified to be regulated by all these five TFs in this pattern, Figure 4E, right down panel). Since the shared
Figure 3: Pattern finding and sub-network construction. A. TF co-regulation network in different regulation pattern (Solid circles distributed along inner ring stand for TFs, edges link the circles and outer ring stand for target genes of TFs, different color of circles and edges stand for different expression pattern of TFs and their targets); B. The overlap of TFs in different regulation pattern; C. The overlap of target genes in different regulation pattern.
Figure 4: TF target profile similarity analysis and module finding. A.B.C.D. Target profile similarity between the TFs in (UM pattern, TNBCov pattern, TNBCac pattern, All the above); E. Co-regulation modules found in UM pattern, TNBCov pattern, TNBCac pattern.
35 genes (details listed in Supplementary Table 1) were insufficient to perform GO enrichment analysis, we explored the TF-target regulation network in TNBC, including genes that were not directly targeted but only a few steps away (described in Methods section). Finally 1,590 genes (including the initial 35 genes) were recruited for GO analysis. GO terms in three categories (response to stimulus, immune response and signal transduction) were found most significantly enriched in these 1,590 genes (Table 2). Stem cell related GO terms and epithelial-mesenchymal transition (EMT) related GO terms were also found significant ($p<0.05$) in our analysis.

### Table 1: Co-Regulation TF modules in all three patterns

| Co-Regulation in Different Pattern | Co-Regulation TF Groups |
|-----------------------------------|-------------------------|
| UM TFs Co-Regulation             | 1. FOXD1, SPI1, NR4A2   |
|                                   | 2. ELK1, ELK4, SPI1    |
|                                   | 3. TCF3, STAT1, STAT3, SPI1 |
|                                   | 4. TLX1, KLF4, MYCN, SPI1 |
| TNBCov TFs Co-Regulation         | 1. FEV, SPIB, ETS1, ZEB1 |
|                                   | 2. ETS1, ZEB1, (RXRA, NFYA, PAX2, POU5F1) |
|                                   | 3. POU5F1, FOXA2       |
|                                   | 4. RUNX1, NFE2L2, (NFYA, FEV) |
|                                   | 5. EN1, PAXB, MAX      |
| TNBCac TFs Co-Regulation         | 1. SOX10, M2F1, ZEB1, ETS1, GATA2 |
|                                   | 2. NFIC, SOX10, M2F1, ZEB1, ETS1, GATA2, (YY1, SPI1) |
|                                   | 3. NFE2L1, MAFG, (GATA3, SPIB, FEV) |

### Table 2: GO enrichment analysis of the sub-network extended by 35 core genes (1590 genes included)

| GOBPID  | P-value   | Count | Term                              |
|---------|-----------|-------|-----------------------------------|
| GO:0002376 | 7.34E-35 | 364   | immune system process             |
| GO:0001775 | 4.90E-31 | 184   | cell activation                   |
| GO:0048518 | 5.98E-31 | 562   | positive regulation of biological process |
| GO:0048584 | 1.62E-26 | 254   | positive regulation of response to stimulus |
| GO:0048583 | 1.82E-26 | 429   | regulation of response to stimulus |
| GO:0006955 | 4.21E-26 | 236   | immune response                   |
| GO:0050896 | 4.29E-25 | 860   | response to stimulus              |
| GO:0045321 | 5.43E-25 | 140   | leukocyte activation              |
| GO:0002682 | 1.38E-24 | 206   | regulation of immune system process |
| GO:0048522 | 2.95E-23 | 489   | positive regulation of cellular process |
| GO:0007165 | 7.83E-22 | 621   | signal transduction               |
| GO:0023052 | 9.51E-22 | 669   | signaling                         |
| GO:0044700 | 9.51E-22 | 669   | single organism signaling         |
| GO:0007154 | 3.19E-21 | 674   | cell communication                |
| GO:0046649 | 3.88E-21 | 119   | lymphocyte activation             |
| GO:0051716 | 4.09E-21 | 714   | cellular response to stimulus     |
| GO:0051239 | 4.66E-21 | 309   | regulation of multicellular organismal process |
| GO:0006950 | 5.36E-21 | 437   | response to stress                |
| GO:0042110 | 1.12E-20 | 96    | T cell activation                 |
validating the previous findings that TNBC was associated with cancer stem cell (CSC) and EMT process [34, 35] (Supplementary Figure 2).

**TNBCac cores TFs are functionally essential in cancer cells**

To test whether the predicted core genes were essential, we further conducted an integrated analysis combining CCLE expression data and Achilles shRNA screening data. Among the 5 core TFs identified in the largest TNBCac co-regulation module, ETS1 and GATA2 seemed to be not generally crucial in survival and growth of cancer cells (Supplementary Figure 3A), which may be due to nonlinear dose-dependence or insufficient shRNA interference efficiency. All MZF1 shRNAs, 4 out of 5 SOX10 shRNAs, and 2 of 3 ZEB1 shRNAs exhibited a strong effect on nearly all 212 cell lines (Supplementary Figure 3B), suggesting that these 3 TFs could be functionally essential in cancer cells.

Furthermore, clustering 13 breast cancer cell lines with shRNA scores of MZF1, SOX10 and ZEB1, could roughly distinguish TNBC cell lines from nTNBC cell lines (Figure 5A). Of note, only two nTNBC cell lines BT474 and EFM19 were clustered together with TNBC cell lines, whereas all TNBC cell lines were clustered in the same group. In contrast, analysis of the expression data of these TFs only was unable to reproduce the clusters (Figure 5B), indicating that our network analysis provides significant new biological insights of these TFs. Representative shRNA score distributions of MZF1, SOX10 and ZEB1 were displayed in HCC1187 (Figure 5C) and ZR7530 (Figure 5D).

The 35 core target genes were also investigated. Generally, these genes are functionally essential in cancer cells (Supplementary Figure 3C), and their shRNA scores could precisely distinguish TNBC cell lines from nTNBC cell lines without any mismatch (Figure 5E). The expression data of these genes had a moderate accuracy in discriminating TNBC from nTNBC cells (Figure 5F), suggesting that the difference of these target genes in TNBC and nTNBC was mainly at expression level.

**In vitro validation of the core TFs' essentialness and regulatory role in TNBC**

To validate the essentialness of the core TFs (MZF1, SOX10 and ZEB1) in different breast cancer cell lines, four TNBC and four nTNBC cell lines were used for CCK8 cell proliferation analysis. Two different siRNAs of each core TFs were transfected in all eight cell lines (Figure 6A&6D, Supplementary Figure 4A), and the ones with better interfering efficiency were used for subsequent CCK8 and RT-qPCR analysis. After silencing of each core TFs, TNBC but not nTNBC cell proliferation rate changed significantly (Figure 6B and 6C, Supplementary Figure 4B, the only exception was siMZF1 in MCF7 cells). Thus our results, both in silico and in vitro, indicated that these 3 TFs were functionally essential for TNBC but not for nTNBC cell proliferation.

To validate the TF-target correlation of core TFs in breast cancer cell lines, 13 of the 35 core target genes were assessed by RT-qPCR after silencing of each core TFs in two nTNBC cells (MCF-7/ZR75) and TNBC cells (HS578T/MB231). The expression fold change of the target genes after MZF1 silencing in nTNBC cells was not significantly correlated with predicted nTNBC MZF1-target edge Z-scores (MCF-7, R=0.299, p=0.320; ZR75, R=0.041, p=0.895, Figure 6E and 6F). However, fold change in TNBC cells was significantly correlated with predicted TNBC MZF1-target edge Z-scores (HS578T, R=0.612, p=0.026; MB231, R=0.564, p=0.044). Silencing of SOX10 and ZEB1 also achieved similar results (Supplementary Figure 5), suggesting that regulatory relationships between these 3 TFs and the core target genes were TNBC specific as predicted.

**TNBCac pattern recapitulates TNBC status and is associated with survival**

The 35 core genes and their co-regulators (not only TFs in TNBCac patterns) were collected as a novel gene signature, and clinical application of this gene signature was explored in several datasets.

Clustering result of TCGA breast cancer patients by these genes had high accordance with the NORM-nTNBC-TNBC classification (Figure 7A). Nearly all TNBC were classified into the same subgroup (Cluster 3) which has the worst prognosis, and the only two TNBC patients classified to the other subgroup (Cluster 1) were still alive till last follow-up (Figure 7B), suggesting the tumor in these patients was less aggressive.

We further stratified nTNBC patients into two subgroups according to similarity with the TNBCac pattern. Strikingly, the subgroup that more resembles TNBC turned out to have a worse prognosis than the other subgroup (Figure 7C), suggesting that the TNBCac signature can also be used as a guide to identify more aggressive nTNBC tumors. To test if this prediction is robust, we applied the same analysis to two independent breast cancer datasets (NKI and GSE3494), and achieved similar results (Figure 7D–7G).

**DISCUSSION**

Although the molecular traits of breast cancer have been discussed in previous reports, studies addressing the regulatory spectrums of breast cancer subtypes were rare [10–12]. Using network topologies and gene expression differences among NORM, nTNBC and TNBC tissues, we distinguished three different TF-gene regulatory patterns,
Figure 5: Essentialness evaluation of core TFs and their co-targeted genes in TNBCac pattern in breast cancer.
A. Heatmap and hierarchical clustering result of 13 Achilles breast cancer cell lines by siRNA scores of 3 Core TFs; B. Heatmap and hierarchical clustering result of 13 Achilles breast cancer cell lines by mRNA expression level of 3 Core TFs; C. Rank and siRNA scores of 3 Core TFs in HCC1187 cell line; D. Rank siRNA scores of 3 Core TFs in ZR7530 cell line; E. Heatmap and hierarchical clustering result of 13 Achilles breast cancer cell lines by siRNA scores of 35 Core co-targeted genes; F. Heatmap and hierarchical clustering result of 13 Achilles breast cancer cell lines by mRNA expression level of 35 Core co-targeted genes.
which reflected three different biological regulatory modes. The TNBCac pattern exhibited a highly significant TF-TF co-regulatory mode. On the contrary, the TFs involved in UM pattern showed a very weak relationship with each other. Thus TNBC may directly originate from NORM instead of nTNBC. This hypothesis is consistent with the fact that transition from nTNBC to TNBC was barely observed in clinical patients [3]. Considering that TF-TF co-regulation was much more significant in TNBCac than in TNBCov, the process of initiating TNBC would more possibly be TF activation driven than TF overexpression driven.

Figure 6: Essentialness validation of core TFs in breast cancer cell lines. A. Silencing of ZEB1, MZF1, SOX10 by two siRNAs in nTNBC cells (MCF-7 and ZR75); B. Cell proliferation cure after silencing of ZEB1, MZF1, SOX10 in nTNBC cells; C. Correlation between predicted TF-target Z-score and target gene expression fold change after silencing of MZF1 in nTNBC cells; D. Silencing of ZEB1, MZF1, SOX10 by two siRNAs in TNBC cells (HS578T and MB231); E. Cell proliferation cure after silencing of ZEB1, MZF1, SOX10 in TNBC cells; F. Correlation between predicted TF-target Z-score and target gene expression fold change after silencing of MZF1 in TNBC cells.
Figure 7: Clustering breast cancer patients by 35 core genes and their regulators, and survival analysis. A. Heatmap and hierarchical clustering result of TCGA breast cancer patients by 35 core genes and their regulators, 3 subgroups were isolated according to the hierarchical tree; B. Kaplan-Meier curve of DMFS in TCGA breast cancer patients, grouped by clustering result; C. Kaplan-Meier curve of DMFS in TCGA breast cancer patients, all patients were grouped to TNBC, nTNBC with same core expression profile with TNBC, and other nTNBC; D. Heatmap and k-means clustering result of validating DATASET1 by 35 core genes and their regulators; E. Kaplan-Meier curve of DMFS in validating DATASET1, all patients were grouped to TNBC, nTNBC with same core expression profile with TNBC, and other nTNBC; F. Heatmap and k-means clustering result of validating DATASET2 by 35 core genes and their regulators; G. Kaplan-Meier curve of DMFS in validating DATASET2, all patients were grouped to TNBC, nTNBC with same core expression profile with TNBC, and other nTNBC.
A core co-regulatory module with 5 TFs and 35 co-targeted genes was identified in TNBCac pattern, and these genes were positioned in the network which is highly associated with response to stimulus, immune response and signal transduction. For response to stimulus, seven related GOs were found in the top20 significant GOs. Previous studies also indicated that stimulus response was highly associated with EMT process, and environmental stress strongly affected the metabolic activity in breast cancer cells [34, 35]. For immune response, six related GOs were found in the top20 significant GOs. Immune response is complicated and could affect carcinogenesis by inflammation [36, 37], autoimmune [38] and immune escape [39] in TNBC. Our findings further indicated that this field was remarkable. For signal transduction, four related GOs were found in the top20 significant GOs. Many signaling pathways such as MAPK, Wnt, and Erk, were found crucial in TNBC [40–43], which could validate our findings.

Furthermore, the essentialness of these genes in cancer cell survival was investigated, especially the core 5 TFs in TNBCac pattern. MZF1, SOX10 and ZEB1 shRNAs displayed strong effect on survival of cancer cells. However, ETS1 and GATA2 seemed to be less crucial in the same system, which might be due to nonlinear dose-dependence or insufficient shRNA interference efficiency. When ruling out the two puzzling TFs, 3 core TFs in the module could still clearly distinguish TNBC cells from nTNBC cells by their essentialness scores, The expression of the 3 core TFs could not distinguish TNBC from nTNBC like their essentialness scores, suggesting that the importance of these 3 TFs in TNBC would mainly due to possible activation process (e.g. post-translational modification) but not the change at expression level.

MZF1 was found crucial in osteopontin-driven MSC-to-CAF transformation, which promoted tumor growth in a microenvironment dependent manner [44]. MZF1 is also a regulator of ERCC1 and affects DNA damage/repair pathway, which is essential in chemoresistance [45]. SOX10 was reported to be preferentially overexpressed in TNBC [46] and appeared to be a part of a highly coordinated transcriptional program characteristic for basal-like features [47]. As a well-studied TF, ZEB1 was highly involved in EMT process and also reported promoting migration in TNBC cells by regulating androgen receptor (AR) [44]. Additionally, it could also enhance tumorigenicity and breast cancer cell plasticity [48]. The 3 core TFs were all found to influence TNBC crucially, but their co-activation was not reported. Our results suggested exploring them as a whole module propounds a further investigation of their co-regulation and co-targeting profile.

Additionally, the core targets genes showed a distinct discrimination between TNBC and nTNBC, not only at essentialness score level but also at expression level, which confirmed our hypothesis that the core 3 TFs promoted TNBC related biological process by regulation of the expression of the core target 35 genes.

Classifying breast cancer by only three markers (ER, PgR, HER2) is rough, and the definition of TNBC did not seem to be rigorous [1, 8, 13]. Recently, development of new technology and algorithm makes it possible to divide breast cancer patients to subgroups more scientifically [1, 13]. Focusing on the heterogeneity of TNBC, many sub-classification systems were developed. However, the heterogeneity of nTNBC was not so appealing even though the prognosis of which varies much more [1]. By clustering patients with our own signature based on the core module found in TNBC, nearly all TNBC patients were clustered into the same subgroup while some nTNBC patients were also clustered with TNBC. In other words, we identified a TNBC-like nTNBC subgroup, which also showed a similar prognosis as TNBC. Furthermore, this classification system was applied in three different cohorts with more than 1000 patients, which conferred this signature close to clinical translation. Compared with the most widely used breast cancer molecular classification system PAM50, which included genes with certain functions in breast cancer [49, 50], our signature focused mainly on translational regulatory features in TNBC and included a whole co-regulatory module. There is little overlap in candidate genes between PAM50 and our signature, so that our signature would be a very important complement to PAM50.

In summary, we established TF-gene regulatory networks in TNBC, found three different patterns, and identified a core TF co-regulatory module comprised of 5 TFs and 35 target genes. These core genes exhibited strong effect on cancer cell survival and growth. Furthermore, the 3 core TFs could distinguish nTNBC cell lines from TNBC cell lines by their “essentialness profile”. The 35 core target genes could distinguish nTNBC cell lines from TNBC cell lines by both expression profile and “essentialness profile”. The overall expression profile of the core targets and their regulators identified a TNBC-like subgroup of nTNBC, whose prognosis was more analogous to TNBC than to other nTNBC, suggesting a promising clinical application perspective. Generally, our results demonstrated a novel and biologically reasonable view to TNBC and enabling nTNBC subtype re-classification based on a TNBC-associated manner. In addition, the methods we described here are not only limited to the analysis of TNBC but also are generalizable to other complicated diseases that demonstrate subtype-specific characteristics, especially those without well-defined molecular targets.
MATERIALS AND METHODS

Data acquisition and preparation

Microarray gene expression data from 63 normal breast (NORM) tissue samples, 445 non-triple-negative breast cancer (nTNBC) tissue samples and 89 triple-negative breast cancer (TNBC) tissue samples were downloaded from TCGA (http://cancergenome.nih.gov/) for primary analysis and TF-targets network construction [25, 26]. Datasets NKI (http://ccb.nki.nl/data/) and GSE3494 (http://www.ncbi.nlm.nih.gov/geo/) were used for validation [31, 32]. Robust Multichip Average (RMA) [51] method was used for normalization.

Position weight matrix (PWM) data of 130 core TF binding sequence motifs in vertebrates were downloaded from JASPAR database [52]. Each motif matrix is used to scan the entire human genome and a threshold value of \( p < 10^{-5} \) was used to determine motif sites. For each motif, we determined its target genes as those whose promoter regions, defined as \([-750, 250] \) base-pairs flanking their transcriptional start sites (TSS), contain at least one motif site. For protein-protein interactions (PPI), we used a publicly available dataset as an estimate [53].

The Cancer Cell Line Encyclopedia (CCLE) (http://www.broadinstitute.org/ccle) database and Achilles database (http://www.broadinstitute.org/achilles) [27–30] were downloaded. 212 cell lines (13 breast cancer cell lines included) with both mRNA expression data and shRNA level scores data were integrated for subsequent analyses.

Network construction and comparison

The PANDA software (http://sourceforge.net/projects/panda-net/) was used for network construction [19, 23, 24]. Networks of NORM, nTNBC and TNBC were constructed by integrating the corresponding TCGA expression, TF motif and PPI data (update parameter \( \alpha = 0.25 \)). A cutoff of FDR adjusted \( p < 0.05 \) was used to determine significant edges.

TFs co-regulation analysis and target profile merging

The hypergeometric distribution model was applied to evaluate the overlap between target genes shared by different TFs. All significant 2-TFs co-regulation genesets were mutually merged for intersections. Genes intersected from four or three 2-TFs co-regulation genesets were defined as 4-TFs or 3-TFs co-regulation genesets, respectively, and then were evaluated with the same hypergeometric distribution model. Larger (5-8-TFs) gene sets were gained by a next merging step with all significant 4-TFs co-regulation genesets.

Core network extension and GO enrichment analysis

The core 35 target genes were reset to TNBC network and their neighbors in this network were looked up by a “network walking” method as described in the following. All TFs regulated more than 10 of these 35 genes were selected as intermediators, while all genes co-regulated by more than 20 intermediators were chosen as neighbors of these 35 genes and used for gene ontology (GO) enrichment analysis (biological process [BP] category, performed by R packages). The hypergeometric distribution model along with a false discovery rate (FDR) adjustment was used for significance evaluation.

Cell culture, small interfering RNAs transfection and CCK8 analysis

Breast cancer cell lines MCF7, ZR75, MDA435, MDA453, MB231, BT20, HS578T, and HCC1937 were purchased from American Type Culture Collection (ATCC) and maintained in standard conditions. Transfection was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Targeted sequences for small interfering RNA (siRNA)-induced silencing were all listed in Supplementary Table 2.

Cell suspension (100 μL/well) was inoculated in a 96-well plate, pre-incubated in a 37°C humidified incubator (5% CO2). After each of the 0, 24, 48, and 72 h time points, 10 μL of the CCK8 reagent from Sigma (St. Louis, MO) was added to each well of the corresponding plate. The plate was incubated for two additional hours and the 450nm absorbance was measured.

Western blot and real-time RT–qPCR

Cell total RNA was extracted with Trizol reagent (Invitrogen) and cDNA was synthesized from at least 3μg of total RNA using oligo (dT) and random hexamer primers. All primers (synthesized by GenePharma) used for RT–qPCR were listed in the Supplementary Table 3, and qPCR settings were 94°C for 2 min followed by 35 cycles of 94°C 15 s, 56°C 20 s and 72°C 30 s and then followed by 72°C for 2 min.

Cell total proteins were obtained by homogenization in 2× loading buffer, resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subjected to western blot with corresponding antibodies. Anti-MZF1 and anti-SOX10 antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-ZEB1 antibody was purchased from Abcam (Cambridge, MA).

Patients clustering and survival analysis

All patients were clustered by a k-means method, where \( k \) was set to 3 (NORM, nTNBC and TNBC) or 2 (when only nTNBC and TNBC were considered). Genes
were clustered by hierarchical clustering. Expression levels of all genes were normalized by row before heatmap visualization. Kaplan-Meier analysis and Log-rank test were used to evaluate survival rates.

**Statistical analysis**

All statistical tests were 2-sided and performed using R 3.1.2 software (www.r-project.org). p<0.05 was considered statistically significant unless otherwise mentioned. A cutoff value of FDR<0.1 was used for multiple comparisons. R packages ggplot2, VennDiagram, and pheatmap were used for data visualization; Mygene, GEOquery and GOstats were used for gene symbol mapping and GO enrichment. R packages survival and MASS were used for survival analysis.

**ACKNOWLEDGMENTS**

We thank Dr. Kimberly Glass, the author of PANDA, for her help in our understanding the mechanism of the PANDA software.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**FUNDING**

This work was supported by the National Basic Research Program of China (Grant 2015CB553906).

**Author contributions**

LM carried out the main analysis. LM, LQ, GCY, and CS conceived and designed the study. CZ performed the cellular and molecular experiments. JH helped to perform statistical analysis. LJ and JL helped to analyze data and prepare molecular experimental reagents. LM and CZ draft the manuscript. GCY, LP and CS helped to revise the manuscript. All authors read and approved the final manuscript.

**REFERENCES**

1. Taherian-Fard A, Srihari S, Ragan MA. Breast cancer classification: linking molecular mechanisms to disease prognosis. Briefings in Bioinformatics. 2014; 16:461-474.

2. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydagsuopa R, Kuo W-L, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiology. Cancer Cell. 2006; 10:529-541.

3. Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, Mariani L, Izzo F, D’Onofrio L, et al. Triple positive breast cancer: A distinct subtype? Cancer Treatment Reviews. 2015; 41:69-76.

4. Chavez V, Garimella S, Lipkowitz S. Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. Breast Dis. 2010; 32:13.

5. Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Annals of Oncology. 2012; 23:v119-vi22.

6. Rakha EA, El-Sayed ME, Green AR, Lee AHIS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109:25-32.

7. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. 2008; 26:1275-1281.

8. Irvin WJ, Carey LA. What is triple-negative breast cancer? European Journal of Cancer. 2008; 44:2799-2805.

9. Zhang C, Han Y, Huang H, Min L, Qu L, Shou C. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer. International journal of oncology. 2014; 44:2025-2033.

10. Herold CI, Anders CK. New targets for triple-negative breast cancer. Oncology (Williston Park, NY). 2013; 27:846-854.

11. Masuda H, Baggery KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical cancer research. 2013; 19:5533-5540.

12. Chesler EJ, Lu L, Shou S, Qu Y, Gu J, Wang J, Hsu HC, Mountz JD, Baldwin NE, Langston MA, Threadgill DW, Manly KF, Williams RW. Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nature genetics. 2005; 37:233-242.

13. Raza Al H, Rueda O, Chin S, Curtis C, Dunning M, Aparicio S, Caldas C. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biology. 2014; 15:431.

14. Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D. Methods of integrating data to uncover genotype–phenotype interactions. Nature Reviews Genetics. 2015; 16:85-97.

15. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nature Reviews Genetics. 2009; 10:252-263.
16. Buckingham M, Rigby Peter WJ. Gene Regulatory Networks and Transcriptional Mechanisms that Control Myogenesis. Developmental Cell. 2014; 28:225-238.

17. Charles B, Zachary L, Gina B, Mahadevan L, Brad G, Zhihui W, Gaye H, Chris S, Laurence F, Michael W. Controlling for Gene Expression Changes in Transcription Factor Protein Networks. Mol Cell Proteomics. 2014; 13:13.

18. Jason E, Qasim B, Krin K, Balausi G, Zolta O, Ziv B-J. A Semi-Supervised Method for Predicting Transcription Factor–Gene Interactions in Escherichia coli. PLoS Comput Biol. 2008; 4:14.

19. Glass K, Huttenhower C, Quackenbush J, Yuan G-C. Passing Messages between Biological Networks to Refine Predicted Interactions. PLoS One. 2013; 8:e64832.

20. Lemmens K, Dhillonator T, De Bie T, Monsieurs P, Engelen K, Smets B, Winderickx J, De Moor B, Marchal K. Inferring transcriptional modules from ChIP-chip, motif and microarray data. Genome Biology. 2006; 7:R37.

21. Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, Cottarel G, Kasif S, Collins JJ, Gardner TS. Large-Scale Mapping and Validation of Escherichia coli Transcriptional Regulation from a Compendium of Expression Profiles. PLoS Biology. 2007; 5:e8.

22. Altay G, Emmert-Streib F. Structural influence of gene networks on their inference: analysis of C3NET. Biology Direct. 2011; 6:31.

23. Glass K, Quackenbush J, Silverman E, Celli B, Rennard S, Yuan G-C, DeMeco D. Sexually-dimorphic targeting of functionallyrelated genes in COPD. BMC Systems Biology. 2014; 8:17.

24. Glass K, Quackenbush J, Spentzos D, Haibe-Kains B, Yuan G-C. A network model for angiogenesis in ovarian cancer. BMC Bioinformatics. 2015; 16.

25. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:10.

26. Network. TCGAR, Weinstein J, Collisson E, Mills G, Shaw K, Ozenberger B, Ellrott K, Shmulevich I, Sander C, Stuart J. The Cancer Genome Atlas Pan-Cancer analysis project. Nature genetics. 2013; 45:8.

27. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483:603-307.

28. Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nature Reviews Genetics. 2015; 16:373-374.

29. Cheung E, Cowley G, Weirb B, Boehmb B, Rusinb S, Scottb J, Eastb A, Albib L, Lizotetb P, Wongtb T, Jiamgb G, Hsiaob J, Mermecia C, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. PNAS. 2011; 108:6.

30. Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Setletsy A, Ali LD, Gerath WJF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific Data. 2014; 1:140035.

31. Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A, Yudi P, Hall P, Klaar S, Liu E, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. PNAS. 2005; 102:5.

32. Marc V, Yudong H, Laura VT, Hongyue D, Augustinus H, Dorien V, George S, Johannes P, Chris R, Matthew M, Mark P, Douwe A, Anke W. A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine. 2002; 347:11.

33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Schafer U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (Oxford, England). 2003; 4:249-264.

34. Cursons J, Leuchowius K-J, Waltham M, Tomaskovic-Crook E, Foroutan M, Bracken CP, Redfern A, Crampin EJ, Street I, Davis MJ, Thompson EW. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Communication and Signaling. 2015; 13.

35. Pedro C, Benoit B, Vinothini R, Bart V, Pedro C. Environmental Stress Affects the Activity of Metabolic and Growth Factor Signaling Networks and Induces Autophagy Markers in MCF7 Breast Cancer Cells. Molecular Cellular Proteomics. 2014; 13:13.

36. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Molecular and Cellular Endocrinology. 2014; 382:673-682.

37. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. Cancer Epidemiology Biomarkers & Prevention. 2014; 23:2965-2970.

38. Katayama H, Boldt C, Ladd JJ, Johnson MM, Chao T, Capello M, Sue J, Mao J, Manson JE, Prentice R, Esteva F, Wang H, Disis ML, et al. An autoimmune response signature associated with the development of triple negative breast cancer reflects disease pathogenesis. Cancer Research. 2015.

39. Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated
40. Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proceedings of the National Academy of Sciences. 2014; 111:E5429-E5438.

41. Zhang M-Z, Ferrigno O, Wang Z, Ohnishi M, Prunier C, Levy L, Razzaque M, Horne Williams C, Romero D, Tzivion G, Collard F, Baron R, Atfi A. TGIF Governs a Feed-Forward Network that Empowers Wnt Signaling to Drive Mammary Tumorigenesis. Cancer Cell. 2015; 27:547-560.

42. Gholami S, Chen CH, Gao S, Lou E, Fujisawa S, Carson J, Nnoli JE, Chou TC, Bromberg J, Fong Y. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Therapy. 2014; 21:283-289.

43. García-Castro A, Zonca M, Florindo-Pinheiro D, Carvalho-Pinto CE, Cordero A, Gutierrez del Burgo B, García-Grande A, Manes S, Halhe M, Gonzalez-Suarez E, Planelles L. APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. Carcinogenesis. 2015; 36:574-584.

44. Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O’Regan RM. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Research and Treatment. 2009; 123:139-147.

45. Yan Q-W, Reed E, Zhong X-S, Thornton K, Guo Y, Yu JJ. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochemical Pharmacology. 2006; 71:761-771.

46. Cimino-Mathews A, Subhawong AP, Elwood H, Warzecha HN, Sharma R, Park BH, Taube JM, Illei PB, Argani P. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Human Pathology. 2013; 44:959-965.

47. Ivanov SV, Panaccione A, Nonaka D, Prasad ML, Boyd KL, Brown B, Guo Y, Sewell A, Yarbrough WG. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. British Journal of Cancer. 2013; 109:444-451.

48. Chaffer Christine L, Marjanovic Nemanja D, Lee T, Bell G, Kleer Celina G, Reinhardt F, D’Alessio Ana C, Young Richard A, Weinberg Robert A. Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity. Cell. 2013; 154:61-74.

49. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical cancer research. 2010; 16:5222-5232.

50. Liu R, Zhang W, Liu Z-Q, Zhou H-H. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes. Oncotarget. 2016; 7:21686-21698. doi: 10.18632/oncotarget.7774.

51. Irizarry RA, Hobbs B, Collin F, Beazer YD, Antonells KJ. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics. 2003; 4:249-264.

52. Albin S, Wynand A, Pa Ér Engstro É, Wyeth W, Boris L. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Research. 2004; 32:4.

53. Ravasi T, Suzuki H, Cannistraci CV, Katayama S, Bajic VB, Tan K, Akalin A, Schmeier S, Kanamori-Katayama M, Bertin N, Carninci P, Daub CO, Forrest ARR, et al. An Atlas of Combinatorial Transcriptional Regulation in Mouse and Man. Cell. 2010; 140:744-752.